echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > [Long Story] China Biotech/New Drug's 2020 Revenue Performance List

    [Long Story] China Biotech/New Drug's 2020 Revenue Performance List

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>



    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio



    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio



    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio



    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio






    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio

    5px;">

    75em;box-sizing:border-box ;"> Cinda Bio

    75em;box-sizing:border-box ;"> Cinda Bio

    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.


    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, the company will achieve a total revenue of 3.
    84 billion yuan, and a total of three new drug products Dyotong®, Su Lixin® and Dabova® have been formally approved by the National Medical Products Administration (NMPA) for marketing.


    5px;">

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    5px;">

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    5px;">

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    5px;">

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    5px;">

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    75em;box-sizing:border-box ;"> Betta Pharmaceuticals

    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.


    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, Betta Pharmaceuticals achieved operating income of 1.
    87 billion yuan, an increase of 20.
    36% over the same period last year.
    Kaimana continued to increase its sales volume, achieving commercial sales of more than 1.
    8 billion yuan, and continued to maintain its leading position in the first-generation EGFR-TKI market.
    Kamena's annual sales revenue has exceeded 1 billion yuan for five consecutive years, and its cumulative sales have exceeded 9 billion yuan.
    ( weixin.


    5px;">

    75em;box-sizing:border-box ;"> BeiGene

    5px;">

    75em;box-sizing:border-box ;"> BeiGene

    5px;">

    75em;box-sizing:border-box ;"> BeiGene

    5px;">

    75em;box-sizing:border-box ;"> BeiGene

    5px;">

    75em;box-sizing:border-box ;"> BeiGene

    75em;box-sizing:border-box ;"> BeiGene

    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.


    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>BeiGene's performance in 2020: PD-1 antibody Bezean's sales in the first year reached US$163.
    36 million, which is approximately RMB 1.
    073 billion; the global sales of BTK inhibitor Beyueze reached US$41.
    7 million, which is approximately RMB 274 million.
    yuan.
    BeiGene's performance in 2020: PD-1 antibody Bezean's sales in the first year reached US$163.
    36 million, which is approximately RMB 1.
    073 billion; the global sales of BTK inhibitor Beyueze reached US$41.
    7 million, which is approximately RMB 274 million.
    yuan.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Bristol-Myers Squibb's (BMS) authorized product revenue in China was US$95.
    12 million, a drop from US$221.
    56 million in the same period last year; Amgen's authorized product revenue in China was US$8.
    5 million.
    In the negotiation of the national medical insurance catalogue at the end of 2020, 5 indications of Baiyueze, Baizean and Anjiawei authorized through Amgen's strategic cooperation were all included in the new version of the national medical insurance catalogue.
    Bristol-Myers Squibb's (BMS) authorized product revenue in China was US$95.
    12 million, a drop from US$221.
    56 million in the same period last year; Amgen's authorized product revenue in China was US$8.
    5 million.
    In the negotiation of the national medical insurance catalogue at the end of 2020, 5 indications of Baiyueze, Baizean and Anjiawei authorized through Amgen's strategic cooperation were all included in the new version of the national medical insurance catalogue.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, BeiGene's research and development expenses will be 1.
    29 billion U.
    S.
    dollars, and in 2019 it will be 927.
    34 million U.
    S.
    dollars.
    The increase in R&D expenses is mainly attributable to the continued increase in costs for ongoing and newly launched late-stage critical clinical trials, the R&D expenses related to the advance payment of authorized drug candidates, the development costs related to the cooperation with Amgen, and the additional Preparation for drug registration and production costs related to pre-commercial activities and supply.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">The king of domestic pharmaceutical BD under the wave of global innovation )In 2020, BeiGene's research and development expenses will be 1.
    29 billion U.
    S.
    dollars, and in 2019 it will be 927.
    34 million U.
    S.
    dollars.
    The increase in R&D expenses is mainly attributable to the continued increase in costs for ongoing and newly launched late-stage critical clinical trials, the R&D expenses related to the advance payment of authorized drug candidates, the development costs related to the cooperation with Amgen, and the additional Preparation for drug registration and production costs related to pre-commercial activities and supply.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">The king of domestic pharmaceutical BD under the wave of global innovation ) In 2020, BeiGene's research and development expenses will be 1.
    29 billion U.
    S.
    dollars, and in 2019, it will be 927.
    3 billion U.
    S.
    dollars.
    The increase in R&D expenses is mainly attributable to the continued increase in costs for ongoing and newly launched late-stage critical clinical trials, the R&D expenses related to the advance payment of authorized drug candidates, the development costs related to the cooperation with Amgen, and the additional Preparation for drug registration and production costs related to pre-commercial activities and supply.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">The kingweixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;"> of domestic pharmaceutical BD under the wave of global innovation ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">The kingweixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541112&idx=1&sn=44e2a2915c3e5ebae985a2425e8207c7&chksm=fa1a41f2cd6dc8e4537874a0db979eb82ee7d6de6605bebf771df16ba008749728985644e71d&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;"> of domestic pharmaceutical BD under the wave of global innovation544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>▲The internal R&D pipeline gathers popular targets such as TIGIT, OX40, TIM-3, BCL-2, HPK1, PI3-Kδ, etc.
    ▲The internal R&D pipeline gathers popular targets such as TIGIT, OX40, TIM-3, BCL-2, HPK1, PI3-Kδ, etc.
    ▲The internal R&D pipeline gathers TIGIT, OX40, TIM-3, BCL-2, HPK1, PI3-Kδ Other popular targets ▲The internal R&D pipeline gathers popular targets such as TIGIT, OX40, TIM-3, BCL-2, HPK1, PI3-Kδ, etc.
    544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Junshi Bio5px;">Junshi Bio5px;">Junshi Bio5px;">Junshi Bio5px;">Junshi Bio5px;">Junshi Bio544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, Junshi Bio will achieve revenue of 1.
    595 billion, a year-on-year increase of about 106%, and net profit attributable to the parent is about 1.
    672 billion.
    The company's total assets were 7.
    997 billion yuan, an increase of 81.
    27% from the beginning of the period; the owner's equity attributable to the parent company was 5.
    827 billion yuan, an increase of 95.
    69% from the beginning of the period.
    In 2020, Junshi Bio will achieve revenue of 1.
    595 billion, a year-on-year increase of about 106%, and net profit attributable to the parent is about 1.
    672 billion.
    The company's total assets were 7.
    997 billion yuan, an increase of 81.
    27% from the beginning of the period; the owner's equity attributable to the parent company was 5.
    827 billion yuan, an increase of 95.
    69% from the beginning of the period.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The substantial increase in Junshi Biology's revenue was mainly due to the increase in sales revenue (1.
    003 billion yuan in 2020) of its core product PD-1 antibody teriplizumab injection and revenue from new technology licensing. The substantial increase in Junshi Biology's revenue was mainly due to the increase in sales revenue (1.
    003 billion yuan in 2020) of its core product PD-1 antibody teriplizumab injection and revenue from new technology licensing. 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The company's product pipeline covers five major therapeutic areas including malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543294&idx=1&sn=0f2bdd80e01c5edef0f95b4fceefbcf6&chksm=fa1a4974cd6dc062bd29480441be2f7afc63e29438d2bd024deb43975302bfc7131b76d2d962&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> Junshi Biologics ushered in a blockbuster to go overseas: driven by innovation, based on the local, global layout )
    The company's product pipeline covers five major therapeutic areas including malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases.
    (The company's product pipeline covers five therapeutic areas including malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543294&idx=1&sn=0f2bdd80e01c5edef0f95b4fceefbcf6&chksm=fa1a4974cd6dc062bd29480441be2f7afc63e29438d2bd024deb43975302bfc7131b76d2d962&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>Junshi Biotechnology ushered in a major weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543294&idx=1&sn=0f2bdd80e01c5edef0f95b4fceefbcf6&chksm=fa1a4974cd6dc062bd29480441be2f7afc63e29438d2bd024deb43975302bfc7131b76d2d962&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>overseas market: driven by innovation, based on innovation Local, global layout )544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲PD-1, 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">the first-line treatment of 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">advanced mucosal 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">melanoma was included in the breakthrough therapy program by NMPA
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲PD-1, 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">the first-line treatment of 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">advanced mucosal 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">melanoma was included in the breakthrough therapy program by NMPA
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲PD-1, advanced mucosa544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲PD-1, advanced mucosa544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲PD-1, advanced mucosa544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲PD-1, advanced mucosa▲PD -1 mucosa late544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> first-line treatment of melanoma were included in the program NMPA breakthrough treatments544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> for melanoma were included NMPA breakthrough first-line treatment therapy program544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">melanoma were included NMPA first-line treatment of breakthrough drugs program544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">melanoma is the first-line treatment NMPA is included in the breakthrough drug programThe first-line treatment of melanoma is included in the breakthrough drug program by NMPA
    544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Celestial creature5px;">Celestial creature5px;">Celestial creature5px;">Celestial creature5px;">Celestial creature5px;">Celestial creature544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The net profit attributable to ordinary shareholders of the parent company for the 2020 fiscal year of Tianjing Biotechnology was RMB 471 million, a year-on-year increase of 131.
    71%; operating income was RMB 1.
    543 billion, a year-on-year increase of 5042.
    23%.
    As of the disclosure date of the annual report, the company's current cash reserves are approximately RMB 4.
    8 billion.

    The net profit attributable to ordinary shareholders of the parent company for the 2020 fiscal year of Tianjing Biotechnology was RMB 471 million, a year-on-year increase of 131.
    71%; operating income was RMB 1.
    543 billion, a year-on-year increase of 5042.
    23%.
    As of the disclosure date of the annual report, the company's current cash reserves are approximately RMB 4.
    8 billion. 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲ 2020 fiscal year results544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020 fiscal year results544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲2020 fiscal year results544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲2020 fiscal year results544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020 fiscal year results544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020 fiscal year results▲2020 fiscal year results544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20209,(:ABBV),lemzoparlimab(TJC4)。,lemzoparlimab,lemzoparlimab、。1.
    8lemzoparlimab,20001,2。,lemzoparlimab17.
    4。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020:License out)20209,(:ABBV),lemzoparlimab(TJC4)。,lemzoparlimab,lemzoparlimab、。1.
    8lemzoparlimab,20001,2。,lemzoparlimab17.
    4。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020:License out)20209,(:ABBV),lemzoparlimab(TJC4)。,lemzoparlimab,lemzoparlimab、。1.
    8lemzoparlimab,20001,2。,lemzoparlimab17.
    4。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020:License out)weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020:License out544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲▲544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲▲544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20201231,10.
    388。12.
    4572.
    876。20201231,33.
    834。20201231,10.
    388。12.
    4572.
    876。20201231,33.
    834。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>2021324,(NMPA)®(,RET)RET(NSCLC)。,®(, KIT/PDGFRA)PDGFRA18(PDGFRA D842V)(GIST)。2021324,(NMPA)®(,RET)RET(NSCLC)。,®(, KIT/PDGFRA)PDGFRA18(PDGFRA D842V)(GIST)。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲,7544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲ drug cloud financial data show that imatinib from Pula in the domestic market until the declaration approved in less than 7 months544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲ drug cloud financial data show that imatinib from Pula declaration approved in the domestic market to less than 7 months544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲ medicine Data from Rongyun shows that it took less than 7 months for pratinib to be approved for listing in China544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Yaorongyun data shows that it took less than 7 months for pratinib to be approved for listing in China544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Yaorongyun According to the data, it has been less than 7 months544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">for pratinib from its domestic application to be approved.
    ▲Yorongyun data shows that it is544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">less than 7 months for pratinib from its domestic application to its approval▲Yaorongyun data shows , Platinib has been approved for less than 7 months from the domestic application for listing544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Sansheng Guojian5px;">Sansheng Guojian5px;">Sansheng Guojian5px;">Sansheng Guojian5px;">Sansheng Guojian5px;">Sansheng Guojian544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, realized operating income of 655 million yuan, a decrease of 44.
    37% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 195 million yuan, a decrease of 166.
    70% from the previous year.
    The decline in revenue and profit was mainly due to the company's price adjustment of its main product Yisaipu at the end of October 2020 in order to maintain its market competitive position.
    The prices of Yisaipu 25mg and 12.
    5mg were both reduced by 50%, which affected sales and gross profit.
    In the fourth quarter, the sales revenue was reduced by 100 million yuan due to price cuts to make up for the difference; the listing of the new HER-2 antibody drug Sepprotin invested a lot of sales expenses; the company incurred 340 million yuan of research and development expenses in 2020, an increase of 22.
    00% year-on-year.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247508685&idx=1&sn=6c297a2e8f71a736e3ad1b12711d80cb&chksm=fa1ac247cd6d4b514ffcc13d0eaf03ddc019f69111d33d84b3aba289ea3a13a1b124a5d3ba81&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> Kechuang board Sansheng | HER2 monoclonal antibody Saiputin is on sale, the price is coming! )In 2020, realized operating income of 655 million yuan, a decrease of 44.
    37% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 195 million yuan, a decrease of 166.
    70% from the previous year.
    The decline in revenue and profit was mainly due to the company's price adjustment of its main product Yisaipu at the end of October 2020 in order to maintain its market competitive position.
    The prices of Yisaipu 25mg and 12.
    5mg were both reduced by 50%, which affected sales and gross profit.
    In the fourth quarter, the sales revenue was reduced by 100 million yuan due to price cuts to make up for the difference; the listing of the new HER-2 antibody drug Sepprotin invested a lot of sales expenses; the company incurred 340 million yuan of research and development expenses in 2020, an increase of 22.
    00% year-on-year.
    (In 2020, realized operating income of 655 million yuan, a decrease of 44.
    37% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 195 million yuan, a decrease of 166.
    70% from the previous year.
    Revenue and profit decreased The main reason is that the company adjusted the price of its main product Yisaipu at the end of October 2020 in order to maintain its competitive position in the market.
    The prices of Yisaipu 25mg and 12.
    5mg were both reduced by 50%, which affected sales and gross profit.
    In the fourth quarter, the price cuts made up the difference.
    The sales revenue was reduced by 100 million yuan; the listing of the new HER-2 antibody drug Septopin invested more in sales expenses; the company incurred 340 million yuan in research and development expenses in 2020, a year-on-year increase of 22.
    00%.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247508685&idx=1&sn=6c297a2e8f71a736e3ad1b12711d80cb&chksm=fa1ac247cd6d4b514ffcc13d0eaf03ddc019f69111d33d84b3aba289ea3a13a1b124a5d3ba81&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>Science Innovation Board Sansheng | HER2 single Anti-Ceptin is on sale, the price is coming! )544px;text-align:justify;text-indent:0em;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Sansheng Guojian product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Sansheng Guojian product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Sansheng Guojian product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Sansheng Guojian product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Sansheng Guojian product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Sansheng Guojian product line▲Sansheng Guojian product line544px;text-indent:0em;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Fuhong Henlius/Fosun Pharmaceutical5px;">Fuhong Henlius/Fosun Pharmaceutical5px;">Fuhong Henlius/Fosun Pharmaceutical5px;">Fuhong Henlius/Fosun Pharmaceutical5px;">Fuhong Henlius/Fosun Pharmaceutical5px;">Fuhong Henlius/Fosun Pharmaceutical544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>From the perspective of Fosun Pharma: During the reporting period of 2020, Fosun Pharma’s R&D investment in the pharmaceutical sector was 3.
    670 billion yuan, a year-on-year increase of 17.
    21%; of which, R&D expenses were 2.
    468 billion yuan, a year-on-year increase of 41.
    76%.
    Han Likang (rituximab injection) increased its production scale (2,000L) quickly after approval, and achieved sales revenue of 750 million yuan in 2020, and the use rate of new patients exceeded 50%.
    The new products Su Kexin (Avatropol Maleate Tablets) and Han Triyou (Trastuzumab for Injection) launched in August 2020 will accelerate market access and actively promote their inclusion in countries, provinces and cities.
    In the medical insurance catalog, the realized income is about 140 million yuan.
    From the perspective of Fosun Pharma: During the reporting period of 2020, Fosun Pharma’s R&D investment in the pharmaceutical sector was 3.
    670 billion yuan, a year-on-year increase of 17.
    21%; of which, R&D expenses were 2.
    468 billion yuan, a year-on-year increase of 41.
    76%.
    Han Likang (rituximab injection) increased its production scale (2,000L) quickly after approval, and achieved sales revenue of 750 million yuan in 2020, and the use rate of new patients exceeded 50%.
    The new products Su Kexin (Avatropol Maleate Tablets) and Han Triyou (Trastuzumab for Injection) launched in August 2020 will accelerate market access and actively promote their inclusion in countries, provinces and cities.
    In the medical insurance catalog, the realized income is about 140 million yuan.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>From the perspective of Fuhong Henlius: In 2020, Fuhong Henlius will achieve operating income of approximately RMB 587.
    6 million, an increase of approximately 546% over 2019.
    R&D services and licensing income.
    The company’s first product, Han Likang® (rituximab), was formally approved by the National Food and Drug Administration (NMPA) NDA in February 2019.
    It is China’s first biosimilar drug that can be used for non-Hodgkin’s lymphoma and chronic For the treatment of lymphocytic leukemia, its domestic commercial sales are handled by Jiangsu Fosun, a subsidiary of Fosun Pharma.
    In 2020, about 720,000 Hanlikang® will be shipped out of the factory, of which about 520,000 will be in the second half of the year.
    Based on the profit sharing with its partner Jiangsu Fosun, the company will achieve sales revenue of about 288.
    2 million yuan and realize licensing revenue of about 10.
    4 million yuan.
    Han Quyou® (trastuzumab, EU trade name: Zercepac®) was approved by the European Commission and NMPA in July and August 2020 for the treatment of HER2-positive breast cancer and gastric cancer.
    In 2020, Hanquyou® will achieve a total sales revenue of 136 million yuan in China and Europe.
    Hanquyou® is the first product to be sold and promoted in China led by the company's commercialization team.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247522669&idx=1&sn=a6a71881ac254fd66a9adfe0fae2fb5d&chksm=fa1af9e7cd6d70f19f8086cd6978ee1ebf6ae885a731237075dd8193392696f61126b637fef7&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Fuhong Hanlius: Trastuzumab is included in Shanghai Medical Insurance, and the individual pays 670 yuan/bottle )From the perspective of Fuhong Henlius: In 2020, Fuhong Henlius will achieve operating income of approximately RMB 587.
    6 million, an increase of approximately 546% over 2019.
    R&D services and licensing income.
    The company’s first product, Han Likang® (rituximab), was formally approved by the National Food and Drug Administration (NMPA) NDA in February 2019.
    It is China’s first biosimilar drug that can be used for non-Hodgkin’s lymphoma and chronic For the treatment of lymphocytic leukemia, its domestic commercial sales are handled by Jiangsu Fosun, a subsidiary of Fosun Pharma.
    In 2020, about 720,000 Hanlikang® will be shipped out of the factory, of which about 520,000 will be in the second half of the year.
    Based on the profit sharing with its partner Jiangsu Fosun, the company will achieve sales revenue of about 288.
    2 million yuan and realize licensing revenue of about 10.
    4 million yuan.
    Han Quyou® (trastuzumab, EU trade name: Zercepac®) was approved by the European Commission and NMPA in July and August 2020 for the treatment of HER2-positive breast cancer and gastric cancer.
    In 2020, Hanquyou® will achieve a total sales revenue of 136 million yuan in China and Europe.
    Hanquyou® is the first product to be sold and promoted in China led by the company's commercialization team.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247522669&idx=1&sn=a6a71881ac254fd66a9adfe0fae2fb5d&chksm=fa1af9e7cd6d70f19f8086cd6978ee1ebf6ae885a731237075dd8193392696f61126b637fef7&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Fuhong Hanlius: Trastuzumab is included in Shanghai Medical Insurance, and the individual pays 670 yuan/bottle )From the perspective of Fuhong Henlius: In 2020, Fuhong Henlius will achieve operating income of approximately RMB 587.
    6 million, an increase of approximately 546% over 2019.
    R&D services and licensing income.
    The company’s first product, Han Likang® (rituximab), was formally approved by the National Food and Drug Administration (NMPA) NDA in February 2019.
    It is China’s first biosimilar drug that can be used for non-Hodgkin’s lymphoma and chronic For the treatment of lymphocytic leukemia, its domestic commercial sales are handled by Jiangsu Fosun, a subsidiary of Fosun Pharma.
    In 2020, about 720,000 Hanlikang® will be shipped out of the factory, of which about 520,000 will be in the second half of the year.
    Based on the profit sharing with its partner Jiangsu Fosun, the company will achieve sales revenue of about 288.
    2 million yuan and realize licensing revenue of about 10.
    4 million yuan.
    Han Quyou® (trastuzumab, EU trade name: Zercepac®) was approved by the European Commission and NMPA in July and August 2020 for the treatment of HER2-positive breast cancer and gastric cancer.
    In 2020, Hanquyou® will achieve a total sales revenue of 136 million yuan in China and Europe.
    Hanquyou® is the first product to be sold and promoted in China led by the company's commercialization team.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247522669&idx=1&sn=a6a71881ac254fd66a9adfe0fae2fb5d&chksm=fa1af9e7cd6d70f19f8086cd6978ee1ebf6ae885a731237075dd8193392696f61126b637fef7&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Fuhong Henlius: Trastuzumab enters Shanghai Medical Insurance, and the individual pays 670 yuan/bottle ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247522669&idx=1&sn=a6a71881ac254fd66a9adfe0fae2fb5d&chksm=fa1af9e7cd6d70f19f8086cd6978ee1ebf6ae885a731237075dd8193392696f61126b637fef7&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Fuhong Henlius: Trastuzumab enters Shanghai Medical Insurance, and the individual pays 670 yuan/bottle544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Fuhong Henlius Product Line
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Fuhong Henlius product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Fuhong Henlius product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Fuhong Henlius product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Fuhong Henlius product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Fuhong Henlius product line▲Fuhong Henlius product line544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Gacos5px;">Gacos5px;">Gacos5px;">Gacos5px;">Gacos5px;">Gacos544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>As of December 31, 2020, Jax Pharmaceuticals had annual revenue of 486 million yuan and R&D investment of over 230 million yuan, a year-on-year increase of 66%.

    As of December 31, 2020, Jax Pharmaceuticals had annual revenue of 486 million yuan and R&D investment of over 230 million yuan, a year-on-year increase of 66%.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>,RAS、MYC、RB、I/O,、KRAS,。JAB-3068JAB-3312SHP2,,PD-1、MEK。2021,Ib/IIa。,RAS、MYC、RB、I/O,、KRAS,。JAB-3068JAB-3312SHP2,,PD-1、MEK。2021,Ib/IIa。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20205,SHP2。,4500(2.
    95),8.
    1(53),SHP2、,,。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247503705&idx=7&sn=811c32581caacdf04a1ece649baf99d5&chksm=fa1aafd3cd6d26c5645695b7a04ba68ea5c5567a6eb895deb556ad9b068889fef9261a2b92b4&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">:AbbVieSHP2)20205,SHP2。,4500(2.
    95),8.
    1(53),SHP2、,,。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247503705&idx=7&sn=811c32581caacdf04a1ece649baf99d5&chksm=fa1aafd3cd6d26c5645695b7a04ba68ea5c5567a6eb895deb556ad9b068889fef9261a2b92b4&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">:AbbVieSHP2)20205,SHP2。,4500(2.
    95),8.
    1(53),SHP2、,,。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247503705&idx=7&sn=811c32581caacdf04a1ece649baf99d5&chksm=fa1aafd3cd6d26c5645695b7a04ba68ea5c5567a6eb895deb556ad9b068889fef9261a2b92b4&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">:AbbVieSHP2)weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247503705&idx=7&sn=811c32581caacdf04a1ece649baf99d5&chksm=fa1aafd3cd6d26c5645695b7a04ba68ea5c5567a6eb895deb556ad9b068889fef9261a2b92b4&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">:AbbVieSHP2544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20208.
    2,98.
    60%,201917.
    68%,(,-)、、(,),36%、53%9%。,,35%、2%7%,。,2020,。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500220&idx=8&sn=b4c4f7eb6c6e94d925174f197d2e1311&chksm=fa1aa136cd6d282077388d3497f6d76d58be50d9e1637a9de8cdb1508273d51de4e7721d6d38&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">,IPO)In 2020, the revenue of Fudan Zhangjiang Pharmaceutical Products was 820 million yuan, accounting for 98.
    60% of the main business revenue, which was a decrease of 17.
    68% compared with the same period in 2019.
    Among them, the main product, Ella (new drug, topical aminolevulinic acid hydrochloride powder-used for treatment Condyloma acuminatum), Libaoduo, and Fumida (new drug, Hemporfin for injection), contributed 36%, 53% and 9% of the company's main business income respectively.
    Affected by the epidemic, sales fell by 35%, 2%, and 7% respectively compared with the same period.
    The epidemic had a significant impact on the performance of dermatology products in particular.
    For specific information, please pay attention to the 2020 annual performance briefing.
    The Pharmaceutical Circle also pays close attention to the new drug companies established in China in the early stage.
    (The weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500220&idx=8&sn=b4c4f7eb6c6e94d925174f197d2e1311&chksm=fa1aa136cd6d282077388d3497f6d76d58be50d9e1637a9de8cdb1508273d51de4e7721d6d38&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">second entry was successful, and the IPO of Fudan Zhangjiang Science and Technology Edition passed the meeting ) In 2020, the revenue of Fudan Zhangjiang's pharmaceutical products was 820 million yuan, accounting for 98.
    60% of the main business revenue, which was a decrease of 17.
    68% compared with the same period in 2019.
    Among them, the main product, Ai La (new drug, topical aminolevulinic acid hydrochloride powder-for the treatment of condyloma acuminatum), Libaoduo, and Fumida (new drug, hemporfen for injection), each contributed 36% to the company's main business income , 53% and 9%.
    Affected by the epidemic, sales fell by 35%, 2%, and 7% respectively compared with the same period.
    The epidemic had a significant impact on the performance of dermatology products in particular.
    For specific information, please pay attention to the 2020 annual performance briefing.
    The Pharmaceutical Circle also pays close attention to the new drug companies established in China in the early stage.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500220&idx=8&sn=b4c4f7eb6c6e94d925174f197d2e1311&chksm=fa1aa136cd6d282077388d3497f6d76d58be50d9e1637a9de8cdb1508273d51de4e7721d6d38&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Second pass through successfully, Fudan Zhangjiang Science and Technology Edition IPO meeting ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500220&idx=8&sn=b4c4f7eb6c6e94d925174f197d2e1311&chksm=fa1aa136cd6d282077388d3497f6d76d58be50d9e1637a9de8cdb1508273d51de4e7721d6d38&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Second pass through successfully, Fudan Zhangjiang Science and Technology Edition IPO meeting544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Zai Lab5px;">Zai Lab5px;">Zai Lab5px;">Zai Lab5px;">Zai Lab5px;">Zai Lab544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Zai Lab will have annual revenue of 49 million U.
    S.
    dollars (approximately 322 million yuan) in 2020, an increase of 277% from 2019.
    R&D expenditures in 2020 will be US$222.
    7 million, an increase of 56.
    6% over 2019.
    Zai Lab will have annual revenue of 49 million U.
    S.
    dollars (approximately 322 million yuan) in 2020, an increase of 277% from 2019.
    R&D expenditures in 2020 will be US$222.
    7 million, an increase of 56.
    6% over 2019.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The core product Zele (Nirapari) sales revenue was 32.
    1 million US dollars (approximately 211 million yuan).
    Nirapali is an oral, once-daily small molecule PARP inhibitor.
    This product entered the medical insurance list in December 2020. The core product Zele (Nirapari) sales revenue was 32.
    1 million US dollars (approximately 211 million yuan).
    Nirapali is an oral, once-daily small molecule PARP inhibitor.
    This product entered the medical insurance list in December 2020. 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Tumor Electric Field Therapy Device (TTF) Epdun's sales revenue was 16.
    4 million US dollars (approximately 108 million yuan).
    Epton is a cancer therapy that uses an electric field adjusted to a specific frequency to block the division of cancer cells, inhibit tumor growth and may cause cancer cells to die.
    It was approved for marketing in June 2020 for the treatment of newly diagnosed glioblastoma (GBM) in combination with temozolomide and as a monotherapy for the treatment of patients with relapsed glioblastoma.
    The Tyrosine Kinase Inhibitor (TKI) Qingle (Repetinib) was approved for marketing in Mainland China and Hong Kong in March 2021 for the treatment of imatinib, sunitinib, and rego Patients with advanced GIST treated with fenib.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247540942&idx=2&sn=76516499ce9189fc2f43f9c3fa8e6d15&chksm=fa1a4044cd6dc952549f575d2740cfadbf9fb4d491dc5cfdf96e41c5c19feb4d5c63cccd8aba&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Domestic Biotech Top: Nearly 120 billion Zai Lab's internal R&D pipelines )Tumor Electric Field Therapy Device (TTF) Epdun's sales revenue was 16.
    4 million US dollars (approximately 108 million yuan).
    Epton is a cancer therapy that uses an electric field adjusted to a specific frequency to block the division of cancer cells, inhibit tumor growth and may cause cancer cells to die.
    It was approved for marketing in June 2020 for the treatment of newly diagnosed glioblastoma (GBM) in combination with temozolomide and as a monotherapy for the treatment of patients with relapsed glioblastoma.
    The Tyrosine Kinase Inhibitor (TKI) Qingle (Repetinib) was approved for marketing in Mainland China and Hong Kong in March 2021 for the treatment of imatinib, sunitinib, and rego Patients with advanced GIST treated with fenib.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247540942&idx=2&sn=76516499ce9189fc2f43f9c3fa8e6d15&chksm=fa1a4044cd6dc952549f575d2740cfadbf9fb4d491dc5cfdf96e41c5c19feb4d5c63cccd8aba&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Domestic Biotech Top: Nearly 120 billion Zai Lab's internal R&D pipelines ) Tumor Electric Field Therapy Device (TTF) Epdun has sales revenue of 16.
    4 million US dollars (about 108 million yuan).
    Epton is a cancer therapy that uses an electric field adjusted to a specific frequency to block the division of cancer cells, inhibit tumor growth and may cause cancer cells to die.
    It was approved for marketing in June 2020 for the treatment of newly diagnosed glioblastoma (GBM) in combination with temozolomide and as a monotherapy for the treatment of patients with relapsed glioblastoma.
    The Tyrosine Kinase Inhibitor (TKI) Qingle (Repetinib) was approved for marketing in Mainland China and Hong Kong in March 2021 for the treatment of imatinib, sunitinib, and rego Patients with advanced GIST treated with fenib.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247540942&idx=2&sn=76516499ce9189fc2f43f9c3fa8e6d15&chksm=fa1a4044cd6dc952549f575d2740cfadbf9fb4d491dc5cfdf96e41c5c19feb4d5c63cccd8aba&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Domestic Biotech Top: Nearly 120 billion Zai Lab’s internal R&D pipeline ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247540942&idx=2&sn=76516499ce9189fc2f43f9c3fa8e6d15&chksm=fa1a4044cd6dc952549f575d2740cfadbf9fb4d491dc5cfdf96e41c5c19feb4d5c63cccd8aba&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Domestic Biotech Top: Nearly 120 billion Zai Lab’s internal R&D pipeline544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Microchip5px;">Microchip5px;">Microchip5px;">Microchip5px;">Microchip5px;">Microchip544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>:20202.
    69,201955.
    05%。,:2015T,20177,。201911。(,weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247548808&idx=1&sn=488cbe73aef30500156d2c007e8e48f0&chksm=fa1a5f02cd6dd6147855ce96081a7ea5204a3909331505e1f4f7954d0b51b2ccd86a65882880&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>:):20202.
    69,201955.
    05%。,:2015T,20177,。201911。(,:20202.
    69,201955.
    05%。,:2015T,20177,。201911。(,weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247548808&idx=1&sn=488cbe73aef30500156d2c007e8e48f0&chksm=fa1a5f02cd6dd6147855ce96081a7ea5204a3909331505e1f4f7954d0b51b2ccd86a65882880&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>:)544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲pipeline▲pipeline544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20201231,2.
    28,20192.
    049。
    20201231,2.
    28,20192.
    049。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>75em;">3,020(1.
    98)(2019:2,680),®()、2,000(2019:1,080);1,020(2019:1,600)。75em;">3,020(1.
    98)(2019:2,680),®()、2,000(2019:1,080);1,020(2019:1,600)。75em;">3,020(1.
    98)(2019:2,680),®()、2,000(2019:1,080);1,020(2019:1,600)。3,020(1.
    98)(2019:2,680),®()、2,000(2019:1,080);1,020(2019:1,600)。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>1.
    748(2019:1.
    382),,,6,330(2019:2,170),1.
    115(2019:1.
    165)。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247547333&idx=1&sn=be3230644f59276728e701780088ecc3&chksm=fa1a594fcd6dd05960f8704944b674d5bdbe377a90a713f6101a8a9a6861784751459a6c73cc&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">【】 | IPO5)1.
    748(2019:1.
    382),,,6,330(2019:2,170),1.
    115(2019:1.
    165)。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247547333&idx=1&sn=be3230644f59276728e701780088ecc3&chksm=fa1a594fcd6dd05960f8704944b674d5bdbe377a90a713f6101a8a9a6861784751459a6c73cc&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">【】 | IPO5)1.
    748(2019:1.
    382),,,6,330(2019:2,170),1.
    115(2019:1.
    165)。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247547333&idx=1&sn=be3230644f59276728e701780088ecc3&chksm=fa1a594fcd6dd05960f8704944b674d5bdbe377a90a713f6101a8a9a6861784751459a6c73cc&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">【】 | IPO5)weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247547333&idx=1&sn=be3230644f59276728e701780088ecc3&chksm=fa1a594fcd6dd05960f8704944b674d5bdbe377a90a713f6101a8a9a6861784751459a6c73cc&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">【】 | IPO5544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(pipeline),20212▲(pipeline),20212
    544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>75em;">Biotech's 2020 annual performance report shows: In fiscal year 202, it achieved operating income of 185 million yuan; research and development expenses of 562 million yuan; net loss attributable to shareholders of listed companies was 513 million yuan, and the loss narrowed by 50% year-on-year.
    75em;">Biotech's 2020 annual performance report shows: In fiscal year 202, it achieved operating income of 185 million yuan; research and development expenses of 562 million yuan; net loss attributable to shareholders of listed companies was 513 million yuan, and the loss narrowed by 50% year-on-year.
    Biotech's 2020 annual performance report shows: In fiscal year 202, it achieved operating income of 185 million yuan; research and development expenses of 562 million yuan; net loss attributable to shareholders of listed companies was 513 million yuan, and the loss narrowed by 50% year-on-year.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>75em;">The company's revenue increased by 184 million yuan over the same period of the previous year, which was mainly due to the company's product Geleli (adalimumab) started to be marketed during the reporting period to generate operating income.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247544855&idx=8&sn=830fe4f211471ade3b2890b1474fcc93&chksm=fa1a509dcd6dd98b19f4afd732fb91ff6c288939c3c0f71aa0999d7b6456721db72847745ffe&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> Biotech! Good job! )
    75em;">The company's revenue increased by 184 million yuan over the same period of the previous year, which was mainly due to the company's product Geleli (adalimumab) started to be marketed during the reporting period to generate operating income.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247544855&idx=8&sn=830fe4f211471ade3b2890b1474fcc93&chksm=fa1a509dcd6dd98b19f4afd732fb91ff6c288939c3c0f71aa0999d7b6456721db72847745ffe&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> Biotech! Good job! )
    The company's revenue increased by 184 million yuan over the same period of the previous year, which was mainly due to the company's product Geleli (adalimumab) started to be marketed during the reporting period to generate operating income.
    (The company's revenue increased by 184 million yuan over the same period of the previous year, mainly because the company's product, Glaly (adalimumab), began to be sold and generated operating income during the reporting period.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247544855&idx=8&sn=830fe4f211471ade3b2890b1474fcc93&chksm=fa1a509dcd6dd98b19f4afd732fb91ff6c288939c3c0f71aa0999d7b6456721db72847745ffe&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>Biotech! Good job! )544px;text-align:justify;white-space:normal;background-color:#FFFFFF;caret-color:#333333;text-size-adjust:auto;font-family:-apple-system, BlinkMacSystemFont, Arial, sans-serif;box-sizing:border-box ;overflow-wrap:break-word ;">75em;">
    75em;">75em;">75em;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;min-height:1em;caret-color:#333333;line-height:1.
    75em;font-family:-apple-system, BlinkMacSystemFont, Arial, sans-serif;box-sizing:border-box ;overflow-wrap:break-word ;">544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Biotech product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Biotech product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Biotech product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Biotech product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Biotech product line544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Biotech product line▲Biotech product line544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Wantai Bio5px;">Wantai Bio5px;">Wantai Bio5px;">Wantai Bio5px;">Wantai Bio5px;">Wantai Bio544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The performance report of Wantai Biotech shows that in 2020, the company will achieve operating income of 2.
    354 billion yuan, a year-on-year increase of 98.
    88%; net profit attributable to shareholders of listed companies is 677 million yuan, a year-on-year increase of 224.
    13%.
    Class 1 new drug product bivalent cervical cancer vaccine (recombinant human papillomavirus 16/18 bivalent vaccine (E.
    coli)) officially went on sale in May 2020, with sales of about 693 million yuan, making the sales revenue and profit of the vaccine business Achieved substantial growth.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247512068&idx=4&sn=b2dae7fdb9d8e1b9e4a5ece6bde8f021&chksm=fa1ad08ecd6d5998504fc08e730de7fb8d08fd564b9151f0f5273197655e5c46b288536b2e54&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> BD transaction|Wanda Biotechnology and Sanofi reached a US$68 million rotavirus vaccine license transaction )The performance report of Wantai Biotech shows that in 2020, the company will achieve operating income of 2.
    354 billion yuan, a year-on-year increase of 98.
    88%; net profit attributable to shareholders of listed companies is 677 million yuan, a year-on-year increase of 224.
    13%.
    Class 1 new drug product bivalent cervical cancer vaccine (recombinant human papillomavirus 16/18 bivalent vaccine (E.
    coli)) officially went on sale in May 2020, with sales of about 693 million yuan, making the sales revenue and profit of the vaccine business Achieved substantial growth.
    ( Wantai Biotech’s performance report shows that in 2020, the company achieved operating income of 2.
    354 billion yuan, a year-on-year increase of 98.
    88%; net profit attributable to shareholders of listed companies was 677 million yuan, a year-on-year increase of 224.
    13%.
    Class 1 new drug product bivalent cervical cancer vaccine (Recombinant human papillomavirus 16/18 bivalent vaccine (E.
    coli)) officially went on sale in May 2020, with sales of about 693 million yuan, which has enabled the sales revenue and profit of the vaccine business to achieve substantial growth.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247512068&idx=4&sn=b2dae7fdb9d8e1b9e4a5ece6bde8f021&chksm=fa1ad08ecd6d5998504fc08e730de7fb8d08fd564b9151f0f5273197655e5c46b288536b2e54&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>BD Transaction| Wantai Biotech and Sanofi reached a US$68 million rotavirus vaccine license transaction )544px;white-space:normal;background-color:#FFFFFF;line-height:1.
    5em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    5em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Yaorongyun data (www.
    ph 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">arnexcloud.
    com) registration timeline, three rounds of supplementary vaccines544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Yorong Cloud Data (www.
    ph 544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">arnexcloud.
    com) registration timeline, three rounds of supplementary vaccines544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> ▲Yorong544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> Cloud Data (www.
    ph544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Yorong Cloud Data (www.
    ph544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Yorong544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Cloud Data (www.
    ph)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Yorong Cloud Data (www.
    ph544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Yorong544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">Cloud Data (www.
    ph▲544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">YorongCloud Data (www.
    ph544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> arnexcloud.
    com) registration timeline, three rounds of supplementary vaccine544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;"> arnexcloud.
    com) registration timeline, experience Three rounds of supplementary vaccine544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">arnexcloud.
    com) registration timeline, three rounds of supplementary vaccine544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">arnexcloud.
    com) registration timeline, three rounds of supplementary vaccine544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">arnexcloud.
    com) registration timeline, three rounds of supplementary vaccinearnexcloud.
    com ) Registration timeline, after three rounds of supplementary vaccines544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap:break-word ;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Tebao Bio5px;">Tebao Bio5px;">Tebao Bio5px;">Tebao Bio5px;">Tebao Bio5px;">Tebao Bio544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, Tebao Bio will achieve operating income of approximately 794 million yuan, a year-on-year increase of 8.
    81%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses is 111 million yuan, a year-on-year increase of 28.
    81%.
    The main reasons for the increase in revenue and profit are: 1.
    With the continuous accumulation of scientific evidence for the clinical cure of chronic hepatitis B, the sales of the company's product Paigabine has grown steadily; 2.
    The cost and expense ratio has shown a downward trend, and government subsidies have increased; financing; Costs have been reduced, and financial income has increased.
    In 2020, Tebao Bio will achieve operating income of approximately 794 million yuan, a year-on-year increase of 8.
    81%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses is 111 million yuan, a year-on-year increase of 28.
    81%.
    The main reasons for the increase in revenue and profit are: 1.
    With the continuous accumulation of scientific evidence for the clinical cure of chronic hepatitis B, the sales of the company's product Paigabine has grown steadily; 2.
    The cost and expense ratio has shown a downward trend, and government subsidies have increased; financing; Costs have been reduced, and financial income has increased.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2016, the company's 14-year national class 1 new drug for biological products, Pegebine, a long-acting interferon, was approved for marketing, becoming the world's first 40kD polyethylene glycol long-acting interferon α-2b injection independently developed in China.
    (weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=3&sn=e94dd7e451aebd737a06b8725129bae6&chksm=fa1af2c9cd6d7bdf0497e87adc8eaab1ed22b5e252f2f70604632c9905828de1e324c551ba48&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'> Aike Baifa and Tebao Biotech reached an exclusive strategic cooperation in the development and commercialization of new hepatitis B drugs in China )2016141——,40kDα-2b。(2016141——,40kDα-2b。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=3&sn=e94dd7e451aebd737a06b8725129bae6&chksm=fa1af2c9cd6d7bdf0497e87adc8eaab1ed22b5e252f2f70604632c9905828de1e324c551ba48&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;'>)544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)▲(www.
    pharnexcloud.
    com)544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>20201410.
    7(9266),160.
    32%;5524.
    4,11.
    66%。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=4&sn=60ee5790013f41ec16be94aa89f1b168&chksm=fa1af2c9cd6d7bdfb1cbd8181677d30bfffb8b046bc4c449370c0d1ad516b4201f91a212913b&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">BD|)20201410.
    7(9266),160.
    32%;5524.
    4,11.
    66%。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=4&sn=60ee5790013f41ec16be94aa89f1b168&chksm=fa1af2c9cd6d7bdfb1cbd8181677d30bfffb8b046bc4c449370c0d1ad516b4201f91a212913b&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">BD|)20201410.
    7(9266),160.
    32%;5524.
    4,11.
    66%。(weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=4&sn=60ee5790013f41ec16be94aa89f1b168&chksm=fa1af2c9cd6d7bdfb1cbd8181677d30bfffb8b046bc4c449370c0d1ad516b4201f91a212913b&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">BD|)weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247520835&idx=4&sn=60ee5790013f41ec16be94aa89f1b168&chksm=fa1af2c9cd6d7bdfb1cbd8181677d30bfffb8b046bc4c449370c0d1ad516b4201f91a212913b&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">BD|544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
    544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲2020/▲2020/
    544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">5px;">5px;">5px;">5px;">5px;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The 2020 performance report shows that the company achieved total operating income of 46,622,800 yuan, an increase of 123.
    50% over the previous year; the net profit loss attributable to the owners of the parent company was 230.
    7275 million yuan, an increase of 19.
    89% over the previous year.
    During the reporting period, the company's operating income increased by 123.
    50% over the same period of the previous year.
    Based on the different characteristics of Aikening (generic name: Abwetai) as an injection, long-acting drug and oral medicine, and its safety and effectiveness in clinical applications have been further verified, the product is in the target patient population.
    Product penetration rate has increased.
    (The weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500763&idx=2&sn=2435e813de1a006ff7a2254f2153cc09&chksm=fa1aa351cd6d2a4700fc8029a8605a0e18913d4e29d0b8c1f206b5bf922958483ca10d7f9282&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">sprint for the cutting-edge biological science and technology board is coming soon, 50 million yuan will be introduced to the Shanghai Institute of Drugs! )The 2020 performance report shows that the company achieved total operating income of 46,622,800 yuan, an increase of 123.
    50% over the previous year; the net profit loss attributable to the owners of the parent company was 230.
    7275 million yuan, an increase of 19.
    89% over the previous year.
    During the reporting period, the company's operating income increased by 123.
    50% over the same period of the previous year.
    Based on the different characteristics of Aikening (generic name: Abwetai) as an injection, long-acting drug and oral medicine, and its safety and effectiveness in clinical applications have been further verified, the product is in the target patient population.
    Product penetration rate has increased.
    (The weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500763&idx=2&sn=2435e813de1a006ff7a2254f2153cc09&chksm=fa1aa351cd6d2a4700fc8029a8605a0e18913d4e29d0b8c1f206b5bf922958483ca10d7f9282&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">frontier biotechnology innovation board is about to sprint, 50 million yuan will be introduced to the Shanghai Institute of Drugs! ) The 2020 performance report shows that the company achieved total operating income of 46,622,800 yuan, an increase of 123.
    50% over the previous year; net profit attributable to owners of the parent company The loss was RMB 230,727,500, an increase of 19.
    89% over the previous year.
    During the reporting period, the company's operating income increased by 123.
    50% over the same period of the previous year.
    Based on the different characteristics of Aikening (generic name: Abwetai) as an injection, long-acting drug and oral medicine, and its safety and effectiveness in clinical applications have been further verified, the product is in the target patient population.
    Product penetration rate has increased.
    (The weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500763&idx=2&sn=2435e813de1a006ff7a2254f2153cc09&chksm=fa1aa351cd6d2a4700fc8029a8605a0e18913d4e29d0b8c1f206b5bf922958483ca10d7f9282&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">sprint of the cutting-edge biotechnology innovation board is coming soon, 50 million yuan will introduce new drugs from the Shanghai Institute of Medicine! ) The weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247500763&idx=2&sn=2435e813de1a006ff7a2254f2153cc09&chksm=fa1aa351cd6d2a4700fc8029a8605a0e18913d4e29d0b8c1f206b5bf922958483ca10d7f9282&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">sprint of the cutting-edge biotechnology innovation board is coming soon, and 50 million yuan will introduce new drugs from the Shanghai Institute of Medicine!544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Cancino5px;">Cancino5px;">Cancino5px;">Cancino5px;">Cancino5px;">Cancino544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>In 2020, Cansino realized operating income of RMB 24,890,400, a year-on-year increase of 990.
    06%; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of -521,740,300 yuan, an increase of 199.
    09% year-on-year loss.
    During the reporting period, losses continued to increase.
    The main reason was that the company increased R&D investment and R&D expenses rose sharply; the company actively promoted the progress of product commercialization, and the number of employees and various operating expenses continued to increase.
    In 2020, Cansino realized operating income of RMB 24,890,400, a year-on-year increase of 990.
    06%; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of -521,740,300 yuan, an increase of 199.
    09% year-on-year loss.
    During the reporting period, losses continued to increase.
    The main reason was that the company increased R&D investment and R&D expenses rose sharply; the company actively promoted the progress of product commercialization, and the number of employees and various operating expenses continued to increase.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The company has promoted the research and development of a series of innovative vaccines.
    The research and development pipeline covers the prevention of meningitis, Ebola virus disease, DPT, pneumonia, tuberculosis, new coronavirus (COVID-19), herpes zoster and other clinical needs.
    Large variety of vaccines.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543480&idx=5&sn=1220b58a2bed7204275715b6aa173e28&chksm=fa1a4a32cd6dc324a61ca8fb059be8443c4094703c229c616bdc4aba4974c4819074a3343e8f&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">"Protective efficacy of 65.
    7%", China's first single-dose new crown vaccine phase III interim analysis announced, from the Academy of Military Medical Sciences/Kangsino )The company has promoted the research and development of a series of innovative vaccines.
    The research and development pipeline covers the prevention of meningitis, Ebola virus disease, DPT, pneumonia, tuberculosis, new coronavirus (COVID-19), herpes zoster and other clinical needs.
    Large variety of vaccines.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543480&idx=5&sn=1220b58a2bed7204275715b6aa173e28&chksm=fa1a4a32cd6dc324a61ca8fb059be8443c4094703c229c616bdc4aba4974c4819074a3343e8f&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">"Protective effectiveness of 65.
    7%", China's first single-dose new crown vaccine phase III interim analysis was announced, from the Academy of Military Medical Sciences/Cansino ) The company has promoted the research and development of a series of innovative vaccines, and the research and development pipeline covers the prevention of meningitis and Ebola virus There are many vaccine varieties that are in large clinical demand, such as disease, DPT, pneumonia, tuberculosis, new coronavirus (COVID-19), and herpes zoster.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543480&idx=5&sn=1220b58a2bed7204275715b6aa173e28&chksm=fa1a4a32cd6dc324a61ca8fb059be8443c4094703c229c616bdc4aba4974c4819074a3343e8f&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">"Protective efficacy 65.
    7%", China's first single-dose new crown vaccine Phase III interim analysis released, from the Academy of Military Medical Sciences/Kangsino ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247543480&idx=5&sn=1220b58a2bed7204275715b6aa173e28&chksm=fa1a4a32cd6dc324a61ca8fb059be8443c4094703c229c616bdc4aba4974c4819074a3343e8f&scene=21#wechat_redirect" data-itemshowtype="11" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">"Protective efficacy 65.
    7%", China's first single-dose new crown vaccine Phase III interim analysis released, from Academy of Military Medical Sciences/Consino544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>On February 25, 2021, the State Food and Drug Administration has conditionally approved the registration application of Cansino recombinant new coronavirus vaccine (type 5 adenovirus vector, trade name "Kweisha").
    On February 25, 2021, the State Food and Drug Administration has conditionally approved the registration application of Cansino recombinant new coronavirus vaccine (type 5 adenovirus vector, trade name "Kweisha").
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">Nuocheng Jianhua5px;">Nuocheng Jianhua5px;">Nuocheng Jianhua5px;">Nuocheng Jianhua5px;">Nuocheng Jianhua5px;">Nuocheng Jianhua544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>The company's revenue and other income increased from 105.
    7 million yuan in 2019 to 272.
    7 million yuan in 2020 (non-drug sales data).
    With the approval of the BTK inhibitor obritinib at the end of 202, the company expects that its revenue sources will be more diversified in 2021.
    The company's R&D expenditure has increased from 213.
    1 million yuan in 2019 to 402.
    8 million yuan in 2020.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247542840&idx=5&sn=3e882b368eb106501372bc9893596e0d&chksm=fa1a48b2cd6dc1a45d6f894c56bfb80b0dd794f24055c81d32395865d50fc24fa50639490042&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Heavy weight! Nuocheng Jianhua Placement raised over 3 billion Hong Kong dollars, Hillhouse strategic investment 2.
    768 billion Hong Kong dollars )The company's revenue and other income increased from 105.
    7 million yuan in 2019 to 272.
    7 million yuan in 2020 (non-drug sales data).
    With the approval of the BTK inhibitor obritinib at the end of 202, the company expects to have more diversified sources of income in 2021.
    The company's R&D expenditure has increased from 213.
    1 million yuan in 2019 to 402.
    8 million yuan in 2020.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247542840&idx=5&sn=3e882b368eb106501372bc9893596e0d&chksm=fa1a48b2cd6dc1a45d6f894c56bfb80b0dd794f24055c81d32395865d50fc24fa50639490042&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Heavy weight! Nuocheng Jianhua's placement raised over HK$3 billion, Hillhouse's strategic investment of HK$2.
    768 billion ) The company's revenue and other income increased from 105.
    7 million in 2019 to 272.
    7 million in 2020 (non-drug sales data) .
    With the approval of the BTK inhibitor obritinib at the end of 202, the company expects to have more diversified sources of income in 2021.
    The company's R&D expenditure has increased from 213.
    1 million yuan in 2019 to 402.
    8 million yuan in 2020.
    ( weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247542840&idx=5&sn=3e882b368eb106501372bc9893596e0d&chksm=fa1a48b2cd6dc1a45d6f894c56bfb80b0dd794f24055c81d32395865d50fc24fa50639490042&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Heavy weight! Nuocheng Jianhua raised more than 3 billion Hong Kong dollars through placement, Hillhouse strategic investment 2.
    768 billion Hong Kong dollars ) weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247542840&idx=5&sn=3e882b368eb106501372bc9893596e0d&chksm=fa1a48b2cd6dc1a45d6f894c56bfb80b0dd794f24055c81d32395865d50fc24fa50639490042&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Heavy weight! Nuocheng Jianhua raised more than 3 billion Hong Kong dollars through placement, Hillhouse's strategic investment was 2.
    768 billion Hong Kong dollars544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;white-space:normal;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;white-space:normal;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;">2020 performance of other new drugs5px;">2020 performance of other new drugs5px;">2020 performance of other new drugs5px;">2020 performance of other new drugs5px;">2020 performance of other new drugs5px;">2020 performance of other new drugs544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Anlotinib of Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceuticals, is 4.
    0-4.
    5 billion; the third-generation EGFR Ametinib of Hausen Pharmaceuticals is 1 billion+; Hengrui Medicine’s PD-1 is 6 billion; CSPC's butylphthalide 3.
    38 billion in the first half of the year, 6 billion is expected for the whole year; etc.
    The space is limited, and the performance of other Biotech companies will be supplemented in the future to show or contact the pharmaceutical industry.
    Anlotinib of Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceuticals, is 4.
    0-4.
    5 billion; the third-generation EGFR Ametinib of Hausen Pharmaceuticals is 1 billion+; Hengrui Medicine’s PD-1 is 6 billion; CSPC's butylphthalide 3.
    38 billion in the first half of the year, 6 billion is expected for the whole year; etc.
    The space is limited, and the performance of other Biotech companies will be supplemented in the future to show or contact the pharmaceutical industry.
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲Pharnexcloud data (www.
    pharnexcloud.
    com) counts the clinical practice of Anlotinib544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)544px;text-size-adjust:auto;font-family:-apple-system, system-ui, Arial, sans-serif;">▲(www.
    pharnexcloud.
    com)▲(www.
    pharnexcloud.
    com)
    544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
    75em;box-sizing:border-box ;overflow-wrap:break-word ;'>,Biotech,。weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247549778&idx=2&sn=692e2b5af403c2de912dbfe681fe55be&chksm=fa1a63d8cd6deaced1839e3ce5e5db9869e8f4646ae2c9c1c1abec42b0a0abbbe6eba8a0a741&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#1C2011;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;caret-color:#1C2011;font-size:15px;letter-spacing:2px;float:none;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;display:inline ;'>(),,!,Biotech,。weixin.
    qq.
    com/s?__biz=MzUyNTgyNjUzMw==&mid=2247549778&idx=2&sn=692e2b5af403c2de912dbfe681fe55be&chksm=fa1a63d8cd6deaced1839e3ce5e5db9869e8f4646ae2c9c1c1abec42b0a0abbbe6eba8a0a741&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="2" hasload="1" style='margin:0px;padding:0px;color:#1C2011;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;caret-color:#1C2011;font-size:15px;letter-spacing:2px;float:none;font-family:, "Microsoft YaHei";box-sizing:border-box ;overflow-wrap:break-word ;display:inline ;'>(),,!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.